Log in to save to my catalogue

Lenvatinib plus pembrolizumab in patients with either treatment-naive or previously treated metastat...

Lenvatinib plus pembrolizumab in patients with either treatment-naive or previously treated metastat...

https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_proquest_miscellaneous_2543453457

Lenvatinib plus pembrolizumab in patients with either treatment-naive or previously treated metastatic renal cell carcinoma (Study 111/KEYNOTE-146): a phase 1b/2 study

Publication information

Publisher

London: Elsevier Ltd

More information

Scope and Contents

Contents

SummaryBackgroundDespite advances in the first-line treatment of metastatic renal cell carcinoma (RCC), there is an unmet need for options to address disease progression during or after treatment with immune checkpoint inhibitors (ICIs). Pembrolizumab and lenvatinib are active as monotherapies in RCC; thus, we aimed to evaluate the combination of l...

Alternative Titles

Full title

Lenvatinib plus pembrolizumab in patients with either treatment-naive or previously treated metastatic renal cell carcinoma (Study 111/KEYNOTE-146): a phase 1b/2 study

Identifiers

Primary Identifiers

Record Identifier

TN_cdi_proquest_miscellaneous_2543453457

Permalink

https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_proquest_miscellaneous_2543453457

Other Identifiers

ISSN

1470-2045

E-ISSN

1474-5488

DOI

10.1016/S1470-2045(21)00241-2

How to access this item